Emetic effects of morphine and piritramide

Area of Science:

• Anesthesiology and Pain Management
• Pharmacology
• Clinical Research

Background:

• Effective postoperative pain management requires balancing analgesia with adverse effects.
• Opioid-induced nausea and vomiting (OINV) negatively impacts patient satisfaction.
• Limited data exists on OINV incidence differences between micro-opioid receptor agonists.

Purpose of the Study:

• To test the hypothesis that the incidence of nausea and vomiting differs between morphine and piritramide.
• To compare OINV rates in patients receiving either morphine or piritramide for patient-controlled analgesia (PCA).

Main Methods:

• A prospective, randomized, double-blind study involving 500 patients (250 per group).
• Morphine or piritramide administered via PCA with a 1.5 mg bolus and 10-min lockout.
• Incidence and intensity of nausea, vomiting, pain, patient satisfaction, side-effects, and drug consumption were measured.

Main Results:

• No significant difference in overall nausea (30% vs 27%) or vomiting (19% vs 15%) incidence between morphine and piritramide groups.
• Mean drug consumption was similar between groups.
• Morphine provided slightly better pain relief at rest and during movement compared to piritramide.

Conclusions:

• Opioid-induced emesis is common, affecting about one-third of patients using morphine or piritramide for PCA.
• Potential differences in vomiting incidence between morphine and piritramide during PCA therapy can be excluded.
• Both agents appear comparable regarding the incidence of opioid-induced vomiting.